Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Share-based Compensation (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Share-based Compensation for 4 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 27.45% to $3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.1 million, a 40.52% increase, with the full-year FY2024 number at $10.6 million, up 39.21% from a year prior.
  • Share-based Compensation was $3.0 million for Q3 2025 at Orchestra BioMed Holdings, down from $3.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.5 million in Q3 2023 to a low of $70000.0 in Q1 2022.
  • A 4-year average of $2.1 million and a median of $2.4 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 2027.14% in 2023, then crashed 32.65% in 2024.
  • Orchestra BioMed Holdings' Share-based Compensation stood at $863000.0 in 2022, then increased by 6.49% to $919000.0 in 2023, then skyrocketed by 215.78% to $2.9 million in 2024, then rose by 3.82% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Share-based Compensation are $3.0 million (Q3 2025), $3.2 million (Q2 2025), and $3.0 million (Q1 2025).